TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36868593

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) administered at different doses and administration intervals during laparoscopic cholecystectomy (LC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG)
Number of subjects: 0
Study: 36868594

Group type: EXPERIMENTAL
Intervention: Computerised decision support tool
Number of subjects: 18

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 18
Study: 36868599

Group type: EXPERIMENTAL
Intervention: Exploratory biomarker analysis, longitudinal characterisation of AECOPD (clinical, functional, and microbial), and identification of host-microbiome interactions.
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Genomic sequencing to identify mutations associated with increased risk of AECOPD and microbial infections.
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Predictors of time-to-first AECOPD modelled using Cox proportional hazards' regression.
Number of subjects: 150
Study: 36868877

Group type: EXPERIMENTAL
Intervention: SCB-2019 (2 doses, administered intramuscularly 21 days apart)
Number of subjects: 30137

Group type: COMPARATOR
Intervention: Placebo (2 doses, administered intramuscularly 21 days apart)
Number of subjects: 30137

Group type: EXPERIMENTAL
Intervention: SCB-2019
Number of subjects: 30137
Study: 36868914

Group type: EXPERIMENTAL
Intervention: Short-term treatment with the BTK inhibitor acalabrutinib and the BCL-2 inhibitor venetoclax
Number of subjects: 0
Study: 36868990

Group type: EXPERIMENTAL
Intervention: ABCB5 treatment (3 intravenous infusions of 2 × 10)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: ABCB5 treatment
Number of subjects: 16
Study: 36869148

Group type: EXPERIMENTAL
Intervention: Combined aerobic exercise and laser phototherapy
Number of subjects: 76

Group type: COMPARATOR
Intervention: Aerobic exercise alone
Number of subjects: 76
Study: 36869208

Group type: EXPERIMENTAL
Intervention: Internal jugular veins compression for 60 seconds to elevate intracranial blood volume and ICP
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Decompressive craniectomy (DC)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: No surgical procedures (Sk1)
Number of subjects: 98
Study: 36869251

Group type: EXPERIMENTAL
Intervention: Abatacept + Methotrexate
Number of subjects: 375

Group type: COMPARATOR
Intervention: Abatacept placebo + Methotrexate
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Continued combination therapy (Abatacept + Methotrexate)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Abatacept monotherapy
Number of subjects: 375
Study: 36869258

Group type: EXPERIMENTAL
Intervention: Gene-present feedback (n=24)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Gene-absent feedback (n=25)
Number of subjects: 49
Study: 36869290

Group type: EXPERIMENTAL
Intervention: Tai Chi program for memory (TCM)
Number of subjects: 41
Study: 36869328

Group type: EXPERIMENTAL
Intervention: Autologous blood localization
Number of subjects: 220

Group type: COMPARATOR
Intervention: Intraoperative colonoscopy
Number of subjects: 220
Study: 36869356

Group type: EXPERIMENTAL
Intervention: filgotinib monotherapy
Number of subjects: 400

Group type: COMPARATOR
Intervention: tocilizumab monotherapy
Number of subjects: 400
Study: 36869364

Group type: EXPERIMENTAL
Intervention: Posterior component separation (CS) with transversus abdominis muscle release (TAR) reinforced by retro-muscular mesh
Number of subjects: 202
Study: 36869371

Group type: EXPERIMENTAL
Intervention: Active surveillance testing with preemptive isolation and contact precautions
Number of subjects: 1314

Group type: COMPARATOR
Intervention: Standard precautions
Number of subjects: 1314
Study: 36869382

Group type: EXPERIMENTAL
Intervention: Early mobility level 4-7 (at least active standing)
Number of subjects: 1708

Group type: EXPERIMENTAL
Intervention: Early mobility level 1-3 (passive transfer from bed to chair or active sitting)
Number of subjects: 1708

Group type: COMPARATOR
Intervention: Early mobility level 0 (passive range of motion)
Number of subjects: 1708
Study: 36869387

Group type: EXPERIMENTAL
Intervention: Test formulation of Voriconazole (4 mg/kg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Test formulation of Voriconazole (6 mg/kg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Reference formulation of Voriconazole (Vfend®) (4 mg/kg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Reference formulation of Voriconazole (Vfend®) (6 mg/kg)
Number of subjects: 48
Study: 36869392

Group type: EXPERIMENTAL
Intervention: Standard care plus music therapy (MT) during hospitalization and/or during a 6-month period post-discharge
Number of subjects: 213

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Standard care plus music therapy (MT)
Number of subjects: 213
Study: 36869680

Group type: EXPERIMENTAL
Intervention: 5-nerve-targeted group (including traditional genicular nerves plus recurrent fibular and infrapatellar branches of the saphenous nerve)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 3-nerve-targeted group (traditional genicular nerves only)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 5-nerve-targeted group
Number of subjects: 80
Study: 36869794

Group type: EXPERIMENTAL
Intervention: Oral cinacalcet
Number of subjects: 65

Group type: COMPARATOR
Intervention: Total parathyroidectomy (PTx)
Number of subjects: 65
Study: 36869793

Group type: EXPERIMENTAL
Intervention: Off-Treatment
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: On-Treatment (systemic treatment)
Number of subjects: 176
Study: 36869878

Group type: EXPERIMENTAL
Intervention: Layered plaque
Number of subjects: 150

Group type: COMPARATOR
Intervention: Non-layered plaque
Number of subjects: 150
Study: 36869909

Group type: EXPERIMENTAL
Intervention: Increased plant protein intake
Number of subjects: 177

Group type: COMPARATOR
Intervention: Decreased plant protein intake
Number of subjects: 177
Study: 36869921

Group type: EXPERIMENTAL
Intervention: Just4Us intervention
Number of subjects: 83

Group type: COMPARATOR
Intervention: Information session (Control)
Number of subjects: 83
Study: 36869990

Group type: EXPERIMENTAL
Intervention: MiFi MVG group (n = 75)
Number of subjects: 500

Group type: COMPARATOR
Intervention: MiFi Conv group (n = 254)
Number of subjects: 500

Group type: COMPARATOR
Intervention: BLZ Conv group (n = 246)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: MiFi MVG group
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 500
Study: 36870019

Group type: EXPERIMENTAL
Intervention: Social Intelligence Training (SIT) program (8 hours)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Attentional Control (AC) condition focusing on healthy lifestyle education
Number of subjects: 230
Study: 36870065

Group type: EXPERIMENTAL
Intervention: On-site CT-FFR care pathway using machine learning
Number of subjects: 1216

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1216
Study: 36870070

Group type: EXPERIMENTAL
Intervention: Triple therapy (hydrocortisone, vitamin C, and thiamine)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 106
Study: 36870093

Group type: EXPERIMENTAL
Intervention: Ganaxolone (maximum daily dose of 63 mg/kg/day if ≤28 kg or 1800 mg/day if >28 kg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ganaxolone
Number of subjects: 21
Study: 36870358

Group type: EXPERIMENTAL
Intervention: Hydroxyurea starting at 20 mg/kg once daily, escalated every 8 weeks by 5 mg/kg per day to maximum tolerated dose.
Number of subjects: 202

Group type: COMPARATOR
Intervention: Usual care from the sickle cell anaemia clinic for participants with normal Doppler velocities (<170 cm/s).
Number of subjects: 202
Study: 36870360

Group type: EXPERIMENTAL
Intervention: Neoadjuvant sintilimab monotherapy (200 mg by intravenous infusion every 21 days)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Neoadjuvant sintilimab monotherapy
Number of subjects: 17
Study: 36870409

Group type: EXPERIMENTAL
Intervention: ZB-06 vaginal film containing HC4-N, used as a single dose before intercourse
Number of subjects: 20

Group type: COMPARATOR
Intervention: No product use (baseline)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No product use (follow-up visit)
Number of subjects: 20
Study: 36870436

Group type: EXPERIMENTAL
Intervention: HR HPV self-sampling
Number of subjects: 400
Study: 36870478

Group type: EXPERIMENTAL
Intervention: Patient's perception of cleansing quality
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Boston Bowel Preparation Scale (BBPS)
Number of subjects: 633
Study: 36870528

Group type: EXPERIMENTAL
Intervention: Virtual Teach-to-Goal (V-TTG)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Brief Intervention (BI)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: V-TTG
Number of subjects: 70

Group type: COMPARATOR
Intervention: BI
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Older children
Number of subjects: 70
Study: 36870539

Group type: EXPERIMENTAL
Intervention: Isolated mixture of crystalline amino acids and fish oil (ISO)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Salmon ingestion (SAL)
Number of subjects: 10
Study: 36870551

Group type: EXPERIMENTAL
Intervention: Gamification
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Financial incentives
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Both gamification and financial incentives
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 1050
Study: 36870572

Group type: COMPARATOR
Intervention: Usual-care control (no portal interventions)
Number of subjects: 213773

Group type: EXPERIMENTAL
Intervention: Pre-commitment messages
Number of subjects: 213773

Group type: EXPERIMENTAL
Intervention: Direct appointment scheduling
Number of subjects: 213773

Group type: EXPERIMENTAL
Intervention: Pre-appointment reminder messages
Number of subjects: 213773
Study: 36870890

Group type: EXPERIMENTAL
Intervention: 1 mcg/kg intranasal dexmedetomidine
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 2 mcg/kg intranasal dexmedetomidine
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 3 mcg/kg intranasal dexmedetomidine
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 4 mcg/kg intranasal dexmedetomidine
Number of subjects: 55
Study: 36870941

Group type: EXPERIMENTAL
Intervention: Paclitaxel NIPEC with systemic paclitaxel and 5-fluorouracil, administered on days 1 and 8, repeated every three weeks for 4 cycles.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paclitaxel NIPEC with systemic paclitaxel and 5-fluorouracil
Number of subjects: 0
Study: 36870948

Group type: COMPARATOR
Intervention: Visual Evoked Potentials (VEPs) in Rett syndrome (n=43) and CDKL5 deficiency disorder (n=16)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Visual Evoked Potentials (VEPs) in MECP2 duplication syndrome (n=15)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Auditory Evoked Potential (AEP) latency in MECP2 duplication syndrome (n=14) and FOXG1 syndrome (n=6)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Auditory Evoked Potential (AEP) amplitude in Rett syndrome and CDKL5 deficiency disorder
Number of subjects: 80

Group type: COMPARATOR
Intervention: Auditory Evoked Potential (AEP) latency in CDKL5 deficiency disorder, MECP2 duplication syndrome, and FOXG1 syndrome
Number of subjects: 80

Group type: COMPARATOR
Intervention: Visual Evoked Potentials (VEPs) in FOXG1 syndrome (n=5)
Number of subjects: 80
Study: 36870947

Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 26
Study: 36870982

Group type: EXPERIMENTAL
Intervention: Partial Caries Removal with Papacarie™ and application Bixa orellana extract (20%) with LED (aPDT)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Partial Caries Removal with Papacarie™ and application Bixa orellana extract (20%)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Partial Caries Removal with Papacarie™
Number of subjects: 160

Group type: COMPARATOR
Intervention: Caries removal with a low-speed drill
Number of subjects: 160
Study: 36871000

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg once daily
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 36871042

Group type: EXPERIMENTAL
Intervention: AZD2811 (500 mg; Day 1; 21-day cycle with G-CSF on Day 8)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: AZD2811 (various doses from 15 to 600 mg)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: AZD2811 (various doses)
Number of subjects: 51
Study: 36871101

Group type: EXPERIMENTAL
Intervention: Pfizer-BioNTech Covid-19 vaccine (2 doses, 21 days apart)
Number of subjects: 35
Study: 36871212

Group type: EXPERIMENTAL
Intervention: Tailored self-management education and support (SMES) program using advertising principles
Number of subjects: 4761

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 4761
Study: 36871213

Group type: EXPERIMENTAL
Intervention: Electronic letters emphasizing cardiovascular benefits of influenza vaccination
Number of subjects: 964870

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 964870
Study: 36871215

Group type: EXPERIMENTAL
Intervention: Eliminating copayments for high-value preventive medications (waived 30% copayment on 15 medication classes)
Number of subjects: 4761

Group type: COMPARATOR
Intervention: Usual copayment (30% copayment on medications)
Number of subjects: 4761
Study: 36871230

Group type: EXPERIMENTAL
Intervention: 3- to 6-month DAPT
Number of subjects: 2013

Group type: COMPARATOR
Intervention: 12-month DAPT
Number of subjects: 2013
Study: 36871246

Group type: EXPERIMENTAL
Intervention: Yuhan rivaroxaban tablet
Number of subjects: 34

Group type: COMPARATOR
Intervention: Xarelto tablet
Number of subjects: 34
Study: 36871285

Group type: EXPERIMENTAL
Intervention: Atrial rate responsive pacing
Number of subjects: 29

Group type: COMPARATOR
Intervention: No pacing
Number of subjects: 29
Study: 36871310

Group type: EXPERIMENTAL
Intervention: Integrated healthcare and vocational rehabilitation intervention (INT)
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: Mental healthcare intervention (MHC)
Number of subjects: 631

Group type: COMPARATOR
Intervention: Service as usual (SAU)
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: MHC
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: INT
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: All interventions (INT, MHC)
Number of subjects: 631
Study: 36871424

Group type: EXPERIMENTAL
Intervention: Pembrolizumab in combination with nab-paclitaxel (nP) and epirubicin/cyclophosphamide
Number of subjects: 50
Study: 36871476

Group type: EXPERIMENTAL
Intervention: Shenlingcao oral liquid (SOL) combined with conventional chemotherapy
Number of subjects: 516

Group type: COMPARATOR
Intervention: Conventional chemotherapy alone
Number of subjects: 516
Study: 36871487

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab with chemotherapy (2 cycles)
Number of subjects: 719

Group type: COMPARATOR
Intervention: Chemotherapy alone (4 cycles)
Number of subjects: 719
Study: 36871573

Group type: EXPERIMENTAL
Intervention: Non-physician community health-care provider-led intensive blood pressure intervention
Number of subjects: 33995

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 33995
Study: 36871574

Group type: EXPERIMENTAL
Intervention: Etrasimod 2 mg
Number of subjects: 433

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 433
Study: 36871613

Group type: EXPERIMENTAL
Intervention: Invasive cardiopulmonary exercise testing
Number of subjects: 35
Study: 36871772

Group type: EXPERIMENTAL
Intervention: FIB-4 <1.3 and/or LSM <8 kp (Class A)
Number of subjects: 2523

Group type: EXPERIMENTAL
Intervention: FIB-4 1.31‒2.6 and/or LSM 8.1-12.5 kp (Class B)
Number of subjects: 2523

Group type: EXPERIMENTAL
Intervention: FIB-4 >2.6 and/or LSM >12.5 kp (Class C)
Number of subjects: 2523
Study: 36871842

Group type: EXPERIMENTAL
Intervention: Impaired spirometry findings (COPD)
Number of subjects: 1561

Group type: EXPERIMENTAL
Intervention: Impaired spirometry findings (COPD GOLD stage ≥ 2)
Number of subjects: 1561

Group type: EXPERIMENTAL
Intervention: Impaired spirometry findings (COPD GOLD stage 1)
Number of subjects: 1561

Group type: COMPARATOR
Intervention: Normal spirometry findings
Number of subjects: 1561
Study: 36871848

Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention (LI)
Number of subjects: 142
Study: 36872017

Group type: EXPERIMENTAL
Intervention: Infant formula with 5-MTHF
Number of subjects: 292

Group type: COMPARATOR
Intervention: Breastfeeding
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Infant formula compliant with EU legislation
Number of subjects: 292

Group type: COMPARATOR
Intervention: TT genotype carriers
Number of subjects: 292
Study: 36872016

Group type: EXPERIMENTAL
Intervention: Healthful plant-based diet (hPDI)
Number of subjects: 65574

Group type: EXPERIMENTAL
Intervention: Unhealthful plant-based diet (uPDI)
Number of subjects: 65574
Study: 36872169

Group type: EXPERIMENTAL
Intervention: Vena cava filters (VCFs) implantation
Number of subjects: 1429
Study: 36872181

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once daily (QD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo QD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg QD
Number of subjects: 0
Study: 36872186

Group type: EXPERIMENTAL
Intervention: Coronary CT angiography (CTA) assessment of hemodynamic and plaque characteristics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Invasive fractional flow reserve (FFR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vessel- and lesion-level hemodynamic characteristics, and vessel-level plaque quantity, and lesion-level plaque compositional characteristics assessed by CTA
Number of subjects: 0
Study: 36872337

Group type: EXPERIMENTAL
Intervention: Sintilimab plus apatinib and chemotherapy
Number of subjects: 30
Study: 36872457

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC) with two cycles of 3-weekly docetaxel 75 mg/m² and concurrent chemoradiotherapy (CCRT)
Number of subjects: 171
Study: 36872873

Group type: EXPERIMENTAL
Intervention: Standard-of-care therapy
Number of subjects: 8007
Study: 36872921

Group type: EXPERIMENTAL
Intervention: Atezolizumab + Bevacizumab
Number of subjects: 501

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 501
Study: 36873397

Group type: EXPERIMENTAL
Intervention: Remnant cholesterol quartile (fourth quartile)
Number of subjects: 2823

Group type: COMPARATOR
Intervention: Traditional risk factors
Number of subjects: 2823
Study: 36873411

Group type: EXPERIMENTAL
Intervention: Acute increase in coronary sinus (CS) pressure during incomplete balloon occlusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham (deflated balloon in the right atrium)
Number of subjects: 20
Study: 36873421

Group type: EXPERIMENTAL
Intervention: Venous ammonia levels
Number of subjects: 549
Study: 36873425

Group type: EXPERIMENTAL
Intervention: Preoperative COVID-19
Number of subjects: 4928

Group type: COMPARATOR
Intervention: No preoperative COVID-19
Number of subjects: 4928
Study: 36873431

Group type: EXPERIMENTAL
Intervention: Satralizumab
Number of subjects: 100
Study: 36873436

Group type: EXPERIMENTAL
Intervention: 10 Hz rTMS over the left PPC for 10 consecutive days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 20
Study: 36873654

Group type: EXPERIMENTAL
Intervention: mHealth nutrition intervention
Number of subjects: 38

Group type: COMPARATOR
Intervention: Wait list control (education) group
Number of subjects: 38
Study: 36873751

Group type: EXPERIMENTAL
Intervention: Combined radiofrequency catheter ablation and LAAC procedures
Number of subjects: 931

Group type: COMPARATOR
Intervention: Control group (men)
Number of subjects: 931
Study: 36873760

Group type: EXPERIMENTAL
Intervention: Complete Revascularization (CR) in PCI
Number of subjects: 600

Group type: COMPARATOR
Intervention: Complete Revascularization (CR) in CABG
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Incomplete Revascularization (IR) in PCI
Number of subjects: 600

Group type: COMPARATOR
Intervention: Incomplete Revascularization (IR) in CABG
Number of subjects: 600
Study: 36873770

Group type: EXPERIMENTAL
Intervention: Clopidogrel monotherapy after 1-month DAPT
Number of subjects: 5982

Group type: COMPARATOR
Intervention: 12-month DAPT with aspirin and clopidogrel
Number of subjects: 5982
Study: 36873828

Group type: EXPERIMENTAL
Intervention: Mental imagery and physical exercise
Number of subjects: 140

Group type: COMPARATOR
Intervention: Only physical exercise
Number of subjects: 140
Study: 36873865

Group type: EXPERIMENTAL
Intervention: OCT investigation in patients with COVID-19 pneumonia
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: OCT as a diagnostic tool
Number of subjects: 13
Study: 36873868

Group type: EXPERIMENTAL
Intervention: ROR1 CAR-T cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapies targeting other tumor antigens or inhibitors preventing tumor antigenic escape
Number of subjects: 0
Study: 36873949

Group type: EXPERIMENTAL
Intervention: Alcoholic drinks and dietary factors
Number of subjects: 0
Study: 36873989

Group type: EXPERIMENTAL
Intervention: Belimumab, dosage and duration not available
Number of subjects: 0
Study: 36873994

Group type: EXPERIMENTAL
Intervention: Methylone (200 mg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: MDMA (100 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 36874115

Group type: EXPERIMENTAL
Intervention: Sintilimab plus Lenvatinib
Number of subjects: 36
Study: 36874269

Group type: EXPERIMENTAL
Intervention: Vitamin D status (measured as serum levels of 25(OH)D)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 125
Study: 36874396

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg once weekly
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study: 36874582

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no iron supplementation)
Number of subjects: 0
Study: 36875061

Group type: EXPERIMENTAL
Intervention: Intrapleural administration of oncolytic vaccinia virus (1.00E+07 to 6.00E+09 PFU)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intrapleural administration of oncolytic vaccinia virus
Number of subjects: 18
Study: 36875114

Group type: EXPERIMENTAL
Intervention: Comprehensive clinical evaluation, exome sequencing, copy number variation analysis, autoantibody surveys, peripheral blood immunophenotyping, salivary cytokine analyses
Number of subjects: 1
Study: 36875126

Group type: EXPERIMENTAL
Intervention: Polyclonal antibodies avidity resolution tool (PAART)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Label-free techniques (surface plasmon resonance and biolayer interferometry)
Number of subjects: 0